MBS item

73342
=====

In situ hybridisation test of stomach or gastro-oesophageal junction tumour tissue with HER2 IHC score 2+ or 3+ to confirm HER2 gene amplification for trastuzumab eligibility, requested by treating specialist.

Category 6 · Pathology services[Group P7](/groups/P7)

Schedule fee$315.40

100% benefitGP, out of hospital—

85% benefitOut of hospital$268.10

75% benefitIn hospital$236.55

The schedule fee for MBS item 73342 is $315.40. Medicare pays $268.10 (85%) out of hospital, or $236.55 (75%) for a privately admitted patient in hospital. Fee effective 1 January 2016.

Gap for what you charge
-----------------------

Your fee$

Out of hospitalIn hospital (private)

Medicare pays$268.10

Patient gap$47.30

Bulk billing means accepting $268.10 as full payment, with no gap and no extra charges. [Add incentives](/bulk-billing?item=73342)

Item descriptor
---------------

An in situ hybridisation (ISH) test of tumour tissue from a patient with metastatic adenocarcinoma of the stomach or gastro-oesophageal junction, with documented evidence of human epidermal growth factor receptor 2 (HER2) overexpression by immunohistochemical (IHC) examination giving a staining intensity score of 2+ or 3+ on the same tumour tissue sample, requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to HER2 gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme are fulfilled.

[Explanatory notes and rules on MBS Online ↗](https://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&q=73342)

Health fund and DVA rates
-------------------------

Total fee each scheme recognises for this item in hospital.

StateNSWVICQLDSAWATASACTNT

Guides
------

- [How Medicare benefits work: schedule fees, 75%, 85% and 100%](/guides/how-medicare-benefits-work)
- [Medicare safety nets explained: original and extended (EMSN) thresholds for 2026](/guides/medicare-safety-nets)
- [In-hospital billing: the 75% benefit, the 25% fund benefit, and no-gap and known-gap schemes](/guides/in-hospital-billing-and-gap-cover)
- [Bulk billing incentives and BBPIP explained: 2026 amounts by MM area](/guides/bulk-billing-incentives)
- [The MBS multiple operation rule and surgical assistant fees](/guides/multiple-operation-rule)
- [Assignment of benefit for bulk billing: the changes from 1 July 2026](/guides/assignment-of-benefit-2026)
- [MBS telehealth rules: the eligible telehealth practitioner and phone items](/guides/mbs-telehealth-rules)
- [GP chronic condition management plans: items 965 and 967 explained](/guides/chronic-condition-management-plans)
- [Medicare billing compliance: claim time limits, records and the 80/20 rule](/guides/medicare-billing-compliance)

Data source: [Australian Government Medicare Benefits Schedule](https://www.mbsonline.gov.au/) · Record updated 1 September 2026. Health fund rates come from each fund's published schedule. Verify item descriptors, rules and fees on [MBS Online](https://www9.health.gov.au/mbs/fullDisplay.cfm?type=item&q=73342) before billing. This is a reference tool, not billing or financial advice.